Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers.

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions.

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals.

DatChat, Inc. a communication software company, develops mobile messaging application. The company offers DatChat Messenger & Private Social Network, a mobile application that gives users the ability to communicate with privacy and protection.

Cyngn Inc., an autonomous vehicle (AV) technology company, develops autonomous driving software. The company is developing Enterprise Autonomy Suite, which consists of DriveMod, a modular industrial vehicle autonomous driving software; Cyngn Insight, a customer-facing tool suite for monitoring and managing AV fleets and aggregating/analyzing data; and Cyngn Evolve, an internal tool suite and infrastructure that facilitates artificial intelligence and machine learning training to enhance algorithms and models, and provides a simulation framework to ensure that data collected in the field can be applied to validating new releases.